Uphill road for Cubist CVRs

Merck taking over Trius, Optimer CVRs, but neither looks likely to pay out

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics Inc. Based on existing and projected sales of the antibiotics tied to the two CVRs, Merck will

Read the full 522 word article

How to gain access

Continue reading with a
two-week free trial.